FDC Ltd

FDC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

FDC Ltd

₹ 388 2.36%
12 Jun - close price
fdcindia.com BSE: 531599 NSE: FDC
About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]

Key Points

Revenue Breakup FY25[1]
Formulations: 92%,
Bulk Drugs : 6%,
Profit share - Formulation: 2%

Website BSE NSE
  • Market Cap ₹ 6,315 Cr.
  • Current Price ₹ 388
  • High / Low ₹ 528 / 313
  • Stock P/E 20.9
  • Book Value ₹ 153
  • Dividend Yield 1.29 %
  • ROCE 16.8 %
  • ROE 12.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 19.4%

Cons

  • The company has delivered a poor sales growth of 9.95% over past five years.
  • Company has a low return on equity of 13.0% over last 3 years.
  • Working capital days have increased from 69.5 days to 123 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
431 530 480 452 454 624 505 459 482 642 462 458 564
377 410 401 370 396 482 433 413 429 501 427 408 453
Operating Profit 54 120 79 82 58 142 72 46 53 141 35 50 112
OPM % 12% 23% 16% 18% 13% 23% 14% 10% 11% 22% 8% 11% 20%
10 30 27 25 21 28 35 19 31 36 21 1 47
Interest 1 1 1 1 1 1 1 1 1 1 1 1 2
Depreciation 10 10 10 10 10 11 14 13 16 15 15 15 14
Profit before tax 53 139 95 96 67 158 92 50 68 161 39 35 143
Tax % 30% 22% 24% 19% 28% 27% 20% 28% 29% 24% 25% 22% 25%
37 109 72 78 48 115 74 36 48 122 29 27 107
EPS in Rs 2.24 6.54 4.42 4.81 2.96 7.06 4.54 2.24 2.96 7.51 1.81 1.67 6.58
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
877 986 1,008 1,061 1,074 1,328 1,323 1,516 1,777 1,916 2,070 2,126
680 759 766 835 854 1,033 999 1,269 1,522 1,578 1,750 1,774
Operating Profit 197 227 242 225 220 295 324 247 255 338 320 352
OPM % 22% 23% 24% 21% 20% 22% 25% 16% 14% 18% 15% 17%
44 40 44 45 51 71 97 79 54 103 106 90
Interest 2 1 1 1 1 3 3 3 4 4 4 5
Depreciation 38 34 35 35 33 37 38 37 39 40 54 59
Profit before tax 201 232 250 234 236 325 380 285 266 398 368 378
Tax % 27% 27% 25% 28% 27% 24% 23% 23% 24% 23% 26% 24%
146 169 187 168 172 247 294 220 201 307 274 286
EPS in Rs 8.20 9.50 10.52 9.65 9.84 14.43 17.45 13.01 12.11 18.87 16.81 17.56
Dividend Payout % 28% 24% 21% 0% 0% 6% 0% 0% 0% 0% 30% 28%
Compounded Sales Growth
10 Years: 8%
5 Years: 10%
3 Years: 6%
TTM: 3%
Compounded Profit Growth
10 Years: 6%
5 Years: 2%
3 Years: 15%
TTM: 13%
Stock Price CAGR
10 Years: 8%
5 Years: 0%
3 Years: 8%
1 Year: -18%
Return on Equity
10 Years: 13%
5 Years: 12%
3 Years: 13%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 18 18 18 18 18 17 17 17 17 16 16 16
Reserves 912 1,059 1,246 1,245 1,416 1,525 1,705 1,932 1,964 2,081 2,271 2,476
1 1 1 1 1 15 14 31 28 20 21 15
209 181 195 224 192 249 207 274 327 341 402 404
Total Liabilities 1,140 1,259 1,459 1,488 1,625 1,806 1,943 2,254 2,335 2,459 2,710 2,912
381 671 674 670 678 670 685 701 695 676 848 994
CWIP 29 20 6 13 12 24 19 104 198 261 136 96
Investments 496 325 491 472 585 665 790 886 806 850 1,050 1,070
234 243 287 333 349 447 448 563 637 672 677 752
Total Assets 1,140 1,259 1,459 1,488 1,625 1,806 1,943 2,254 2,335 2,459 2,710 2,912

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
127 171 153 148 104 239 210 162 165 221 310 200
-89 -73 -144 20 -109 -85 -84 -147 4 -18 -199 -109
-47 -97 0 -169 -0 -142 -126 -10 -180 -202 -92 -93
Net Cash Flow -10 1 10 -2 -6 12 -1 5 -11 1 19 -2
Free Cash Flow 81 -135 129 112 62 235 151 36 54 151 220 40
CFO/OP 96% 100% 92% 96% 80% 109% 94% 98% 95% 96% 129% 81%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 25 24 28 26 28 34 30 19 25 22 18 24
Inventory Days 133 134 148 166 183 180 189 210 180 217 185 182
Days Payable 95 85 81 101 82 101 68 94 100 104 102 106
Cash Conversion Cycle 64 73 95 92 130 113 151 135 106 134 102 100
Working Capital Days 12 22 24 28 44 41 47 45 48 52 33 123
ROCE % 21% 22% 21% 19% 18% 22% 22% 15% 13% 18% 16% 17%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Medical Representatives (Field Force)
Count

Log in to view insights

Please log in to see hidden values.

Login
Market Share - Electral (ORS)
%
Market Share - Zifi (Cefixime)
%
Number of Dealers/Distributors
Count
Market Share - Enerzal
%
Monthly Production Capacity - Sinnar ORS Sachets
Million Units
US FDA Approved ANDAs (Cumulative)
Count
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
69.49% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.65%
2.06% 2.42% 2.43% 2.65% 2.51% 2.62% 2.67% 2.56% 2.41% 2.43% 2.32% 2.40%
9.13% 8.12% 7.76% 6.94% 6.72% 6.02% 6.08% 6.37% 7.17% 6.81% 6.27% 6.29%
19.32% 19.80% 20.15% 20.76% 21.11% 21.71% 21.60% 21.42% 20.76% 21.10% 21.76% 21.65%
No. of Shareholders 56,71756,92855,34152,37750,63455,40055,22853,88054,44554,15753,78852,730

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls